Microbes were the only life form on Earth for most of the history of our planet. Even today, they still make up the majority of species that are vital to the health of our planet. […]
Reusing data collected in clinical studies is of strong scientific and economic interest. Anonymisation has emerged as a solution to extend data life, while providing regulatory compliance and privacy protection. Nevertheless, true anonymisation of complex […]
ProDigest has been awarded a contract to provide a SHIME® (Simulator of Human Intestinal Microbial Ecosystem) technology platform for full gut simulation to the US Food and Drug Administration (FDA), National Center for Toxicological Research. […]
32 Biosciences, pronounced “Three Squared Biosciences,” announces its emergence from stealth mode, with new microbiome diagnostic management tools and microbiome-based interventions. The company intends to revolutionize healthcare with its novel approach to gut microbiome medicine. […]
Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today reports topline clinical data from Cohort 2 of its SER-155 Phase 1b placebo-controlled study in patients undergoing allo-HSCT. In this patient population, infections are […]
dsm-firmenich, a global innovator in health, nutrition and beauty, today announced the successful approval of its human milk oligosaccharide (HMO): 3-fucosyllactose (3-FL) and lacto-N-fucopentaose I/2′-fucosyllactose (LNFP-I/2′-FL) mixture as novel food ingredients in the United Kingdom […]
Viome, a pioneer in microbiome health science and personalized health solutions, today announced a $25 million internal Series D with participation from Khosla Ventures, Bold Capital WRG Ventures, Marc Benioff, and more. This continued support from existing backers […]
Lallemand announces the inauguration of its new laboratories in France, increasing its capacity by over 800 square meters. This significant expansion enhances its interdisciplinary research and development capabilities at the Blagnac and Beauzelle sites. The […]
Infant Bacterial Therapeutics has conducted a phase III study comprising 2153 premature infants for five years. The objective of the study has been to show that the company’s drug candidate IBP-9414, a bacterial strain found […]
ZBiotics, the pioneers carving a new category of genetically engineered probiotics, today announced the close of its $12M Series A funding round, led by Spring Tide Capital. The oversubscribed round also includes participation by Access Capital, Seamless Capital, Goat […]
The novel active agent HY-133, which was developed by HYpharm and prepared for clinical trials in collaboration with the German Center for Infection Research (DZIF) and universities in Tübingen, Munich, Münster and Greifswald, received approval […]